ARCH Venture Partners — Pre-Seed & Seed VC Firm ($1.0M–$20.0M Checks)
ARCH Venture Partners is a Pre-Seed, Seed, Series A venture capital firm based in Chicago, Illinois, United States investing in Healthcare, Deep Tech. The firm typically writes $1.0M–$20.0M checks and has 130 portfolio companies in our records.
- Check size
- $1.0M–$20.0M
- Portfolio
- 130 companies on record
- Partners
- 13 listed
- AUM
- $12B
- Stage
- Pre-Seed, Seed, Series A
- Sectors
- Healthcare, Deep Tech
- HQ
- Chicago, Illinois, United States
Last verified: 2026-11-09
Pre-Seed, Seed, Series A
$1.0M – $20.0M
$12.0B
130+ companies
13 partners
About ARCH Venture Partners
ARCH Venture Partners is a venture capital firm headquartered in Chicago, Illinois. The firm backs disruptive science companies, primarily founding and investing in early-stage life-sciences and technology companies, including companies working to prevent, detect, and cure disease. ARCH Venture Partners often builds companies alongside leading scientists and entrepreneurs.
The firm invests at the pre-seed, seed, and series A stages. Sectors of focus include healthcare, deep tech, and cell therapy. Typical check sizes range from $1.0M to $20.0M. ARCH Venture Partners has assets under management of $12B. A warm introduction is preferred when approaching the firm.
Investment Thesis
ARCH backs disruptive science and builds early-stage companies, primarily in life sciences and physical sciences. Its current focus includes companies developing technologies to prevent, detect, and cure disease.
How ARCH Venture Partners invests
ARCH Venture Partners is a vc firm based in Chicago, Illinois, United States. The firm invests at the Pre-Seed, Seed, Series A stages, with a focus on Healthcare, Deep Tech.
ARCH Venture Partners typically writes checks of $1.0M–$20.0M per investment, backed by approximately $12B in assets under management. Our records include 6 funds raised by the firm.
ARCH Venture Partners has backed 130 companies in our records, including Beam Therapeutics, Lyell Immunopharma, Halo Top.
Partners & Team
Specific partner not identified in source
Partner
Industry Focus
Invests In
Funds
ARCH Venture Partners Fund VI
ARCH Venture Partners Fund V
ARCH Venture Partners Fund IV
ARCH Venture Partners Fund III
ARCH Venture Partners Fund II
ARCH Venture Partners Fund I
Recent Activity
ARCH Venture Partners announcement: One BioMed closes $5M Series A funding round
Nov 2026 · BioSpectrum Asia
ARCH Venture Partners promoted Corey Ritter to Partner
Oct 2026 · ARCH Venture Partners
ARCH-backed City Therapeutics closes $230 million IPO to drive RNAi therapeutics
Oct 2026 · ARCH Venture Partners
ARCH-backed Ramona Optics closes $25M Series A funding round led by ARCH Venture Partners
Sep 2026 · TradingView News
ARCH Venture Fund XIV filed in SEC Form D
Aug 2026 · SEC
Investment Track Record
ARCH Venture Partners has recorded investments in 135 portfolio companies. These include 908 Devices, Accompany Health, Aera Therapeutics, Agios Pharmaceuticals, AIRNA, Akamis Bio, Aledade, Alnylam Pharmaceuticals, Altos Labs, and Arbor Biotechnologies. The firm has also made recorded investments in several of its own venture funds, including ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Fund X, L.P., and ARCH Venture Fund XI, L.P.
The firm's team includes Robert Nelsen, managing director with focus areas in biotech, immunotherapy, and deep tech, along with other partners and operations staff.
Portfolio Companies (130)
Other
Beam Therapeutics
Lyell Immunopharma
Halo Top
Calm
ArsenalBio
Cell therapy company developing programmable cancer treatments.
Metsera
Biotechnology company; ARCH lists it as a Fund XIII investment.
Xaira Therapeutics
Biotechnology company; ARCH lists it as a Fund XIII investment.
Mirador Therapeutics
Moleculent AB
Moonwalk Biosciences
RNA-interference and epigenetic therapeutics platform focused on obesity and cardiometabolic disease
- •Raising at Pre-Seed, Seed, Series A? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare, Deep Tech — the sectors they actively back.
- •Size your ask to their typical $1.0M – $20.0M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Melanie Simms, Director of Operations.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if ARCH Venture Partners is a match for your startup
Upload your pitch deck to see how well you match with ARCH Venture Partners and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal